09/09/2025
Neurescue has secured a historic Class III CE Mark for non‑shockable cardiac arrest treatment❤️ A life-saving breakthrough for the 81% of cardiac arrest patients who cannot be defibrillated. This CE Mark approval is more than a regulatory milestone. It bridges a gap for millions of patients facing the most critical life-threatening condition.